Beyond Episodic Testing: Toward Ambient Monitoring in Heart Failure

Heart failure clinicians have traditionally relied on episodic assessments to evaluate cardiac function and hemodynamic status. Echocardiography, natriuretic peptides, and physical examination remain indispensable tools in clinical practice; however, these measurements are typically obtained only during clinic visits or hospitalizations. As a result, they provide only intermittent snapshots of cardiovascular physiology, offering limited insight into the dynamic physiological changes that occur between encounters.This episodic model of monitoring may be particularly problematic in heart failure, a condition in which hemodynamic and neurohormonal deterioration often begins days or even weeks before clinical symptoms become apparent. Subtle alterations in cardiac mechanics, respiratory dynamics, or autonomic regulation may precede overt decompensation. Detecting these early pathophysiological changes has therefore become a central goal in modern heart failure management, especially during the vulnerable period following hospitalization [1]. Importantly, episodic testing is largely reactive, whereas emerging monitoring strategies aim to enable more proactive and predictive care by identifying early fluctuations in cardiac function and hemodynamic status before clinical instability develops [2].Advances in sensing technology and digital health are now making it increasingly feasible to capture physiological signals continuously and unobtrusively within a patient’s everyday environment. These developments are giving rise to a new paradigm of ambient physiological monitoring, in which physiological data are collected not only during clinical testing but throughout daily life. In this evolving framework, heart failure monitoring is shifting beyond episodic testing toward continuous, environment-integrated physiological sensing [3, 4], as conceptually illustrated in Figure 1.In this issue of Cardiology, Wu and colleagues present a proof-of-concept study demonstrating the feasibility of noncontact monitoring of cardiac function using a fiber-optic micro-vibration sensing system embedded within a mattress [5]. The system captures subtle mechanical vibrations generated by cardiac contraction and blood flow, enabling estimation of the myocardial performance index (MPI), a parameter originally proposed by Tei and colleagues [6] that integrates systolic and diastolic time intervals into a single measure of global ventricular function.In their study, cardiac intervals derived from vibration signals showed strong correlations with echocardiographic measurements, and the MPI estimated by the fiber-optic micro-vibration sensing system demonstrated excellent agreement with echocardiographic MPI. Moreover, the system exhibited high diagnostic performance in identifying patients with heart failure with reduced ejection fraction. Among continuously monitored patients, temporal changes in the vibration-derived MPI were also associated with short-term clinical outcomes, suggesting that continuous monitoring of cardiac mechanical signals may provide clinically meaningful information about disease status without requiring direct patient contact.Beyond the technical performance of the sensing method, the broader significance of this study lies in the conceptual shift it represents. Technologies such as the fiber-optic micro-vibration sensing system suggest that clinically relevant physiological information may be captured continuously and noninvasively within the patient’s environment, either instead of or in addition to intermittent measurements obtained in clinical settings. Such approaches bring physiological monitoring closer to patients’ daily lives and may enable earlier recognition of disease fluctuations, thereby creating opportunities for more timely adjustments of therapy and more personalized management strategies.Indeed, several physiological monitoring approaches are currently being explored in this context. Remote monitoring technologies capable of detecting early changes in hemodynamic status, respiratory patterns, or autonomic activity are increasingly being investigated for home-based management of heart failure [3]. For example, respiratory dynamics have been studied as potential indicators of worsening heart failure in telemonitoring systems [7]. Beyond in-home monitoring, advances in imaging technologies have also enabled assessment of cardiopulmonary motion using dynamic chest radiography, providing another noninvasive approach to evaluating cardiopulmonary physiology [8].From a broader perspective, these developments align with the emerging paradigm of digital cardiovascular medicine, in which physiological signals are captured continuously through unobtrusive sensing technologies integrated into the patient’s environment [4]. Rather than relying solely on intermittent clinical testing, future heart failure management may incorporate ambient monitoring systems capable of identifying early pathophysiological changes and supporting dynamic, personalized treatment strategies. Achieving this vision will require not only advances in sensing technologies but also robust digital infrastructures, data integration platforms, and clinical frameworks capable of translating continuous physiological data into actionable clinical insights.Several questions remain to be addressed. The present study was conducted in a relatively small cohort and focused primarily on diagnostic performance rather than longitudinal clinical outcomes. Whether continuous monitoring of vibration-derived MPI can predict heart failure decompensation, hospitalization, or mortality will require further investigation in larger prospective studies. Additionally, factors such as body position, patient movement, and environmental conditions may influence vibration signals and should be carefully evaluated in future research.Nevertheless, the work by Wu et al. offers an intriguing glimpse into a future in which cardiac function may be monitored continuously without direct patient contact. As sensing technologies, signal-processing algorithms, and digital health platforms continue to evolve, ambient physiological monitoring may become an increasingly important component of heart failure care. Ultimately, the value of such technologies will lie not merely in measuring physiological signals, but in enabling earlier recognition of disease instability and facilitating timely, individualized therapeutic interventions.Dr. Takahiro Okumura was a member of the journal’s Editorial Board at the time of submission. Hiroaki Hiraiwa has received research grants from Konica Minolta, Inc., Konica Minolta Science and Technology Foundation, Kowa Life Science Foundation, Suzuken Memorial Foundation, The Nitto Foundation, Kondou Kinen Medical Foundation, The Hori Sciences and Arts Foundation, Chukyo Longevity Medical and Promotion Foundation, Shimadzu Science Foundation, Aichi Health Promotion Foundation, and The Naito Science & Engineering Foundation. Takahiro Okumura is affiliated with a department sponsored by Medtronic (Japan). Takahiro Okumura has received research grants from Pfizer Japan, Alnylam Japan Pharmaceuticals, and Alexion Pharmaceuticals, and lecture fees from AstraZeneca, Pfizer Japan, Alnylam Japan Pharmaceuticals, and Toa Eiyo. Toyoaki Murohara has received honoraria from Bayer, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Kowa, MSD, Mitsubishi Tanabe, Nippon Boehringer Ingelheim, Novartis Pharma, Pfizer Japan, Sanofi, and Takeda Pharma. These relationships are unrelated to the present work.This study was not supported by any sponsor or funder.Hiroaki Hiraiwa drafted the manuscript. Takahiro Okumura and Toyoaki Murohara critically revised the manuscript for important intellectual content.